Artiva Biotherapeutics (ARTV) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$220.5 million.
- Artiva Biotherapeutics' Enterprise Value fell 5035.02% to -$220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.5 million, marking a year-over-year decrease of 5035.02%. This contributed to the annual value of -$185.4 million for FY2024, which is 53451.2% down from last year.
- According to the latest figures from Q3 2025, Artiva Biotherapeutics' Enterprise Value is -$220.5 million, which was down 5035.02% from -$256.3 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Enterprise Value ranged from a high of $73.1 million in Q2 2024 and a low of -$301.6 million during Q1 2025
- Its 3-year average for Enterprise Value is -$116.2 million, with a median of -$106.3 million in 2023.
- The largest annual percentage gain for Artiva Biotherapeutics' Enterprise Value in the last 5 years was 23612.07% (2024), contrasted with its biggest fall of 53451.2% (2024).
- Over the past 3 years, Artiva Biotherapeutics' Enterprise Value (Quarter) stood at $42.7 million in 2023, then crashed by 534.51% to -$185.4 million in 2024, then decreased by 18.89% to -$220.5 million in 2025.
- Its Enterprise Value stands at -$220.5 million for Q3 2025, versus -$256.3 million for Q2 2025 and -$301.6 million for Q1 2025.